Tectonic Therapeutic (TECX) Leerink Global Healthcare Conference 2025 summary

Vision and lead program focus

• TX45 is positioned as a transformational therapy for Group 2 pulmonary hypertension, especially in cpcPH patients with high pulmonary vascular resistance, representing a large U.S. patient population.

• If efficacy extends to HFpEF, the addressable market could nearly double, making it a multi-billion dollar opportunity.

• Encouraged by phase I-B data, additional indications are being considered, and a second program for hereditary hemorrhagic telangiectasia is expected to enter the clinic within a year.

Clinical trial results and expectations

• Phase I-B showed a 17-18% decrease in pulmonary capillary wedge pressure and over 30% reduction in PVR for cpcPH patients, with a 26% drop in total pulmonary resistance.

• Cardiac output increased by about 18%, and pulmonary artery pressure was reduced, indicating improved left heart function and hemodynamics.

• Durability of effect is supported by preclinical and clinical data, including long-term studies in animals and humans, with hints of sustained benefit in early echo data.

• Minor, transient decreases in blood pressure and short-lived fatigue were observed, with no significant safety concerns identified.

Phase II APEX trial design and strategy

• The trial is highly enriched for cpcPH patients with PVR >3 Wood units to maximize the likelihood of demonstrating benefit, especially in the six-minute walk test.

• All background therapies are allowed, and patients must be on stable doses before enrollment to ensure reliable baseline measurements.

• Enrollment requires a pulmonary capillary wedge pressure greater than 15.

• Readout is expected in 2026, with more specific timing to be provided as enrollment progresses.

• Key endpoints include hemodynamic changes and a numeric trend in the six-minute walk test, with a 15-20 meter increase considered clinically meaningful.